Enzyme immunoassay market seen reaching $30.37 billion by 2030

The enzyme immunoassay market is projected to grow from $21.5 billion in 2025 to $30.37 billion by 2030, driven by automation, precision diagnostics and rising infectious disease demand. North America led in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Enzyme immunoassays are a core diagnostic tool for detecting proteins, hormones and infectious agents in samples. - The market’s projected rise to $30.37 billion by 2030 points to stronger demand for faster, more automated testing in clinical labs, research settings and disease monitoring. - Growing infectious disease pressure and broader use of precision diagnostics are expanding the role of these tests in healthcare workflows.

What happened: - The Business Research Company said the global enzyme immunoassay market will grow from $21.5 billion in 2025 to $23.09 billion in 2026. - The company projected the market will reach $30.37 billion by 2030, based on a 7.1% compound annual growth rate. - The release was dated Aug. 6, 2026, and published from London. - The company offered a free sample of the enzyme immunoassay market report.

The details: - Enzyme immunoassay uses antibodies linked with enzymes to detect and measure target molecules in a sample. - The method produces a measurable signal, often a color change, that correlates with the amount of target substance present. - The technique is used for accurate quantitative analysis in diagnostics and research. - The company said earlier growth was supported by limited availability of automated EIA systems, dependence on manual microplate readers, expanding clinical laboratory infrastructure, rising chronic and infectious disease rates, and continued use of traditional reagents and kits. - Future growth is expected to come from fully automated EIA analyzers, personalized medicine, precision diagnostics, laboratory information management systems, software and data analytics tools, and demand from academic and research institutions. - The company also pointed to wider use of automated analyzers, therapeutic drug monitoring, multiplex testing, high-throughput assays, oncology and infectious disease testing, and stronger laboratory data integration as future trends. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covered South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company said its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated trend graphics. - The release identified the full enzyme immunoassay market report as available here.

Between the lines: - The growth story is being shaped by two forces at once: more infectious disease testing and a shift toward automated, data-connected lab systems. - The regional split suggests mature demand in North America and faster expansion in Asia-Pacific as diagnostic capacity grows. - The emphasis on software, analytics and workflow efficiency signals that the market is moving beyond test kits toward integrated lab platforms.

What's next: - Market growth will likely depend on how quickly labs adopt fully automated analyzers and connected information systems. - Demand from oncology, infectious disease testing and therapeutic drug monitoring is expected to remain a major driver through 2030. - The company’s forecast points to continued expansion as clinical and research institutions increase testing volume and automation.